Back

Pharma

Biomanufacturing: Continuous Processing & Digitalisation

  • 22nd – 23rd May 2024
  • Germany flag Germany Munich & Online

The biopharma industry operates under the constant drive to enhance productivity, reduce costs, and ensure product quality and consistency. To meet these demands, continuous biomanufacturing, process intensification and digitalisation have emerged as crucial solutions.

The Biomanufacturing: Continuous Processing & Digitalisation Summit delves into the complexities associated with the development and implementation of continuous and intensified processing in both upstream and downstream operations and leveraging digital capabilities.

While continuous bioprocessing offers remarkable advantages in improving productivity and facility utilisation for companies, digitalisation serves as a vital enabler for smarter bioprocessing, shedding light on the ongoing digital transformation within the bioprocessing industry.

Read more

About the Biomanufacturing: Continuous Processing & Digitalisation Summit

The Biomanufacturing: Continuous Processing & Digitalisation Summit is a premier event that dives deep into the complexities associated with the development and implementation of continuous and intensified processing in both upstream and downstream operations, while also exploring the potential of leveraging digital capabilities.

In today's competitive biopharma industry, continuous bioprocessing, process intensification, and digitalisation have emerged as crucial solutions to enhance productivity, reduce costs, and ensure product quality and consistency. The summit brings together industry experts, thought leaders, and professionals to exchange knowledge, insights, and experiences in these areas.

Throughout the #VLbiomanufact summit, we will primarily focus on key subjects that are at the forefront of biopharmaceuticals manufacturing:

  • Optimising biopharmaceutical process development, manufacturing, cost, and quality efficiency
  • Applying emerging science and new technologies to optimise biopharma production processes
  • Expediting the development of biopharmaceuticals by utilising intensified and continuous processing techniques
  • Integrating continuous processing across upstream and downstream bioprocessing to foster seamless and uninterrupted production
  • Applying intensified processing techniques to novel biologics, enabling efficient production and improving manufacturing capabilities
  • Empowering scientific advancements and operational excellence in biomanufacturing with digitalisation and innovative approaches

By addressing these subjects, the summit aims to provide valuable insights and practical strategies for attendees to enhance their biopharma processes, increase efficiency, and navigate the digital transformation within the industry.

Join us at the Biomanufacturing: Continuous Processing & Digitalisation Summit to engage in dynamic discussions, gain valuable industry knowledge, and network with peers who are shaping the future of biopharma manufacturing. Together, let's explore the forefront of continuous processing, process intensification, and digitalization to drive innovation and success in the biopharma landscape.

See you in-person and online in Munich, Germany, at the #VLbiomanufact 2024!

Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, and Managers specialising in:

  • Advanced Process Control (APC)
  • Analytics
  • Artificial Intelligence (AI)
  • Augmented Reality (AR) and Virtual Reality (VR)
  • Automation and Digital
  • Automation and Control
  • Batch/Fed-Batch Processes
  • Biopharmaceutical Lifecycle Management (BPLM)
  • Bioprocessing
  • Bioproduction
  • Chemistry, Manufacturing, and Controls (CMC)
  • Continuous Manufacturing (CM)
  • Contract Manufacturing
  • Data Analytics
  • Data Management
  • Digital Twins
  • Digitalisation
  • Digital Transformation
  • Downstream Process (DSP)
  • Engineering
  • Facility Management
  • Good Manufacturing Practices (GMP)
  • In-Process Control (IPC)
  • Industry 4.0
  • Innovation Data and Digital
  • Equipment Innovations
  • High Throughput Process Development (HTPD)
  • Machine Learning (ML)
  • Manufacturing
  • Manufacturing, Science, and Technology (MS&T)
  • Modelling and Simulations
  • Modular Facilities
  • Multi-Purpose Facilities
  • Novel Modalities (Biologics, Gene, Cell) and Vaccines
  • Operational Excellence
  • Pharmaceutical Lifecycle Management (LCM)
  • Plant/Site Management
  • Process Analytical Technology (PAT)
  • Process Engineering
  • Process Science
  • Quality
  • Quality Assurance (QA)
  • Quality Control (QC)
  • Quality Risk Management
  • Real-Time Process Control
  • Regulatory
  • Robotics and Automation
  • Sensing Technologies
  • Simulations Tools
  • Supply Chain
  • Upstream Process (USP)

Register by February 16th

REQUEST A BROCHURE

To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.

Key Practical Learning Points

  • Optimising biopharmaceuticals process development, manufacturing, cost, and quality efficiency
  • Applying emerging science and new technologies to optimise biopharma production
  • Expediting the development of biopharmaceuticals by utilising intensified and continuous processing techniques
  • Integrating continuous processing across upstream and downstream bioprocessing to foster seamless and uninterrupted production
  • Applying intensified processing techniques to novel biologics, enabling efficient production and improving manufacturing capabilities
  • Empowering scientific advancements and operational excellence in biomanufacturing with digitalisation and innovative approaches

Register by February 16th

Dr. Jens Smiatek, DE

Digital Lead at Development NCE

Boehringer Ingelheim Pharma GmbH & Co. KG

Jens Smiatek has a PhD and habilitation in theoretical physics. He has taken various group leader positions in universities and research organisations, and his main biotechnological interests include modelling and advanced machine learning of coupled and single unit operations and formulation aspects. He is the author of more than 100 peer-reviewed articles with over 2600 citations (H-index 32). Since 2019, Jens has worked at Boehringer Ingelheim Pharma GmbH & Co. KG.

Dr. Stephan Kirsch, AT

Director of Scientific Office Analytical Development

Novartis

Stephan Kirsch is a versatile leader with interest in operational excellence, digitalisation and innovation, a scientific track record in mass spectrometry, and a focus on biologics drug substance development with major contributions to Zarzio and Beovu.

Dr. Ricardo Silva, PT

Senior Scientist

iBET - Instituto de Biologia Experimental e Tecnológica

Dr. Ricardo Silva graduated in 2008 with a degree in chemical and biochemical engineering from the Faculdade de Cincias e Tecnologia – Universidade Nova de Lisboa and obtained his PhD (2013) in chemical and biochemical engineering with a specialisation in process simulation and optimisation from the same university. In 2014, Ricardo was a senior scientist in the animal cell technology unit at iBET in the downstream process development lab and since 2019 has been in the late-stage R&D unit. Ricardo’s current research topics are related to the development of efficient and integrated downstream processes for the purification of complex biotherapeutic targets, namely cell-based products, mAbs, virus-based biologics, recombinant proteins, and extracellular vesicles.

Moritz von Stosch, CH

Chief Innovation Officer & Board Member

DataHow AG

Dr. Moritz von Stosch is a thought leader in the area of digital process development and manufacturing and an author of more than 40 scientific publications, including the Book “Hybrid Modelling in Process Industries”. He is the chief innovation officer at DataHow AG, and prior to joining DataHow he led the process systems biology and engineering centre of excellence at GSK vaccines, for which he received an Innovation Performance and Trust award and was nominated as a change catalyst.

Dr. Stefan Schmidt, CH

Chief Executive Officer

evitria AG 

Dr. Stefan R. Schmidt, MBA, currently is CEO at evitria AG, a company dedicated to antibody discovery services in Zürich. Previously Stefan led operations at BioAtrium AG, a joint venture of Lonza and Sanofi in Visp, Switzerland, as COO. Before that he held the position of CSO and other senior executive roles at Rentschler Biopharma (Germany) with overall responsibilities for biologics development and manufacturing. Before that, he was CSO at ERA Biotech in Barcelona, Spain, directing the company’s R&D efforts based on fusion proteins. Prior to that, he worked at AstraZeneca in Sweden, where he led the unit of protein sciences within global protein science and supply as associate director. He started his leadership career 25 years ago at biotech companies in Munich, Germany, where he built up protein biochemistry teams for Connex and GPC-Biotech. He holds a PhD in biochemistry from the Julius Maximilians University in Wuerzburg, Germany, and an MBA from the University in Gävle, Sweden.

Dr. Touraj Eslami, AT

Automation Engineer

Austrian Centre of Industrial Biotechnology

As a post-doc and automation engineer at the Austrian Centre for Industrial Biotechnology (ACIB), Touraj Eslami specialised in downstream processing. Touraj is dedicated to enhancing biopharmaceutical manufacturing through advanced control strategies and quality by design (QbD) principles. Touraj is passionate about digitalisation and its potential to enhance productivity, efficiency, and sustainability.

Dr. Edward Close, UK

Bioprocessing Practice Area Director

Siemens Digital Industries

Dr. Edward Close is practice area director for bioprocessing in Siemens Digital Industries Process Automation Software business. He has an engineering doctorate in biochemical engineering from University College London in collaboration with Pfizer. Edward has over 10 years’ experience at Siemens leading the development and application of Siemens mechanistic and hybrid modelling solutions for bioprocessing to deliver value to across the process industries.

Stephen Judd, IR

Process SME - Biologics/Cell & Gene Therapy

Arcadis l DPS Group Global

Stephen Judd is a chartered chemical engineer and fellow of engineers Ireland. He is an experienced technical manager and principal process engineer with more than 15 years’ experience in process engineering and facility design, mainly in biotech projects. He has an excellent mix of design office and field experience across a wide range of international clients with significant experience in process technology selection and facility design. He has experience across the full project life cycle from feasibility study to commissioning and qualification and now focusses on the early project phases developing the facility design and manufacturing philosophies. Stephen has significant experience with different process technologies across all parts of the manufacturing process for biologics, ATMP, and other novel therapies such as SPPS and mRNA vaccines. This includes selecting the optimum approach to suit the specific needs of the client/project with respect to hard-piped, single-use, or hybrid systems.

Stephen has also authored or co-authored a number of technical papers including a paper on multi-modal facility design published in the ISPE PE Magazine. He is actively involved in the development of a number of ISPE guides currently in development relating to C&GT topics.

Dr. Dimitrios Lamprou, UK

Full Professor (Chair) of Biofabrication and Advanced Manufacturing & Director at MSc Industrial Pharmaceutics

Queen’s University Belfast (QUB)

Dimitrios Lamprou (PhD, MBA) is a full professor (chair) of biofabrication and advanced manufacturing, and a director at MSc industrial pharmaceutics at Queen’s University Belfast (QUB). He is also the chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the chair of the Academy of Pharmaceutical Sciences (APS) emerging technologies focus group. Dimitrios is the author of over 150 peer-reviewed publications, has over 350 conference abstracts, has given over 150 invited talks in institutions and conferences across the world, and has secured funding of more than £4M.

Dimitrios has been recognised as a world leader in 3D printing and microfluidics. PubMed-based algorithms placed him in the top 0.088% of scholars in the world writing about 3D printing and in the top 0.071% of scholars in the world writing about microfluidics in the past 10 years. Moreover, PubMed-based algorithms placed him in the top 0.63% of scholars in the world writing about nanofibers.

Dimitrios has also twice been named in Stanford University’s list of the world’s top 2% scientists (2021 and 2022) for his research in pharmaceutics and biomedical engineering. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. For more info, please visit www.emergingtechnologieslab.com.

Dr. Maximilian Krippl, AT

Head of Bioprocess Modelling Consulting

Novasign

Maximilian is the head of bioprocess modelling consulting at Novasign, where he is responsible for modelling projects for upstream and downstream processes. Leveraging his expertise in mathematical modelling, he collaborates with clients to design and accelerate process development and predict and control bioprocess performance. Maximilian holds a master’s degree in technical chemistry from TU Wien and earned his PhD from the prestigious University of Natural Resources and Applied Life Sciences in Vienna, Austria, for which he was awarded the Award of Excellence from the Austrian Ministry of Education, Science and Research.

Dr. Zoltán Kis, UK

Lecturer I Department of Chemical and Biological Engineering

The University of Sheffield & Imperial College London

Rui Almeida, PT

Director, Product Lifecycle Management Services

Valgenesis

Rui Almeida leads ValGenesis’ product lifecycle management consultancy group, offering a range of services where science and engineering are coupled in areas such as process lifecycle management, quality risk management, and CMC strategy. Rui has a licentiate degree in biological engineering and a master's degree in engineering management and nearly two decades of pharmaceutical industry experience, holding senior positions in technical services, quality assurance of IMP/commercial products, and project management in small and large pharmaceutical companies. Prior to joining ValGenesis, he served as PMO group leader in the services business segment of a CDMO.

Fabian Stutz, CH

CEO

Pharmabotix AG

Fabian Stutz is the CEO and founder of Pharmabotix, which is committed to revolutionising pharmaceutical production through innovative automation solutions. Their vision is to assist companies in the pharmaceutical sector in automating and robotising their processes, thereby enhancing the quality of their products, maximising efficiency, and reducing costs. They offer a comprehensive range of services, from feasibility studies to concept development and the realisation of turnkey systems.

Dr. Jens Smiatek, DE

Digital Lead at Development NCE

Boehringer Ingelheim Pharma GmbH & Co. KG

Dr. Stephan Kirsch, AT

Director of Scientific Office Analytical Development

Novartis

Dr. Ricardo Silva, PT

Senior Scientist

iBET - Instituto de Biologia Experimental e Tecnológica

Moritz von Stosch, CH

Chief Innovation Officer & Board Member

DataHow AG

Dr. Stefan Schmidt, CH

Chief Executive Officer

evitria AG 

Dr. Touraj Eslami, AT

Automation Engineer

Austrian Centre of Industrial Biotechnology

Dr. Edward Close, UK

Bioprocessing Practice Area Director

Siemens Digital Industries

Stephen Judd, IR

Process SME - Biologics/Cell & Gene Therapy

Arcadis l DPS Group Global

Dr. Dimitrios Lamprou, UK

Full Professor (Chair) of Biofabrication and Advanced Manufacturing & Director at MSc Industrial Pharmaceutics

Queen’s University Belfast (QUB)

Dr. Maximilian Krippl, AT

Head of Bioprocess Modelling Consulting

Novasign

Dr. Zoltán Kis, UK

Lecturer I Department of Chemical and Biological Engineering

The University of Sheffield & Imperial College London

Rui Almeida, PT

Director, Product Lifecycle Management Services

Valgenesis

Fabian Stutz, CH

CEO

Pharmabotix AG

BROCHURE

Request the Biomanufacturing: Continuous Processing & Digitalisation Summit brochure and find out the latest topics and ideas that will be shared.

Request

Please fill in your e-mail address below and we will process your request in a moment.

What our
participants
are saying

The Summit was an incredibly informative and insightful event. The sessions on continuous processing and process intensification provided valuable strategies and practical approaches for optimizing biopharmaceutical manufacturing. The discussions on digitalization showcased the potential for transformative advancements in the industry. Truly a conference that keeps attendees at the forefront of innovation!.

1
2
3
4
5

PAST

Attendee

I thoroughly enjoyed attending the Summit. The sessions on continuous bioprocessing and intensified techniques provided valuable insights into maximising efficiency and productivity. The discussions on digital transformation were eye-opening, showcasing the power of data-driven decision-making in the biopharma industry. This summit was an exceptional platform for learning, networking, and staying abreast of the latest advancements.

1
2
3
4
5

PAST

Attendee

The Summit was an outstanding event that brought together experts and thought leaders in the biopharma industry. The sessions on process optimization, cost-efficiency, and quality improvement were highly relevant and provided actionable takeaways. The focus on digitalisation and innovative approaches opened up new possibilities for enhancing our manufacturing processes. I am leaving this summit with a wealth of knowledge and valuable connections.

1
2
3
4
5

PAST

Attendee